Hans C. Hasselbalch ^1,2* Vibe Skov ¹ Lasse Kjaer ¹ Trine A. Knudsen ¹ Christina S. Eickhardt-Dalbøge ¹ Christina Ellervik ^2,3 Sabrina Cordua ¹ Anders L. Sørensen ¹ Sarah F. Christensen ¹ Marie H. Kristiansen ^2,4 Jes Lindholt ⁵ Mads Thomassen ⁶ Torben K A. Kruse ⁶ Niels E. Bruun ^2,7 Matias G. Lindholm ^2,7 Claus H. Nielsen ^2,8 Miklos Egyed ⁹ Winfried März ¹⁰ Morten K. Larsen ^1,2 Troels Wienecke ^2,4

• ¹ Department of Hematology, Zealand University Hospital, Roskilde, Denmark
• ² Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Capital Region of Denmark, Denmark
• ³ Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States
• ⁴ Department of Neurology, Zealand University Hospital, Roskilde, Denmark
• ⁵ Department of Cardiothoracic and Vascular Surgery, Odense University Hospital, Odense, Denmark
• ⁶ Department of Clinical Genetics, Odense University Hospital, Odense, Denmark
• ⁷ Department of Cardiology, Zealand University Hospital, Roskilde, Denmark
• ⁸ Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
• ⁹ Department of Hematology, Somogy County Kaposi Mór Teaching Hospital, Kaposvar, Hungary
• ¹⁰ Department of Laboratory Medicine, Heidelberg University, Heidelberg, Germany

Clonal Hematopoiesis of Indeterminate Potential (CHIP) is a precursor stage to the BCR-ABL negative chronic myeloproliferative neoplasms (MPNs). These diseases arise due to mutations in the hematopoietic stem cell. The MPNs are largely underdiagnosed blood cancers with a long pre-diagnostic phase of several years, when the elevated blood cell counts are considered reactive to smoking, blood clots , infections or chronic inflammatory diseases. Since the JAK2V617 mutation as CHIP-JAK2 associates with an increased risk of CVD and an increased risk of hematological and non-hematological cancers there is an urgent need to explore and validate the JAK2 mutation as a novel risk factor for CVD and to establish CHIP-clinics , which in an interdisciplinary collaboration between experts from several disciplines , ensure timely diagnosis of the undiagnosed MPN patient and associated comorbidities.We envisage studies of the JAK2 mutation in large CVD cohorts to deliver the "Proof of Concept" for the JAK2 mutation to implemented as a novel, highly important risk factor for CVD. These novel preventive strategies are considered to have the potential of reducing morbidity and mortality in a large population of citizens and patients, carrying the thrombosis-and CVDpromoting JAK2 mutation.• CHIP-JAK2V617F (JAK2) associates with a chronic inflammatory state and an increased risk of cardiovascular diseases (CVD), including ischemic heart disease and stroke• The JAK2 mutation is envisaged as a novel risk factor for CVD and the CHIP-Clinic as a novel interdisciplinary powerhouse for preventive medicine and much earlier diagnosis of MPNs and associated comorbidities